Evaluation of VEGF Polymorphism as Predictive Factor in Metastatic Colorectal Cancer Treated With Folfiri Plus Bevacizumab

Study ID
NCT01363739

Study type
Observational

Study phase

Study status
Unknown status

Trial Acronym

PROVETTA

Trial Summary

-1498C/T VEGF polymorphism, as suggested by a recent retrospective analysis, seems to have a role in predicting the efficacy of Bevacizumab plus FOLFIRI in first-line treatment of metastatic colorectal cancer patients. The present study aims to prospectively evaluate the predictive role of this polymorphism in metastatic colorectal patients receiving the same treatment.

More informations

Trial Starting Date

Apr 30,2009

Requirements

Gender All
Minimum age N/A
Maximum age N/A

Enrollement Limit

265